$CLRB
Cellectar Biosciences, Inc.

2016 Q4 Form 10-Q Financial Statement

#000114420416133257 Filed on November 10, 2016

View on sec.gov

Income Statement

Concept 2016 Q4 2016 Q3 2015 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.210M $1.160M $830.0K
YoY Change 51.25% 39.76% 3.75%
% of Gross Profit
Research & Development $1.440M $1.306M $1.168M
YoY Change 50.0% 11.8% -20.58%
% of Gross Profit
Depreciation & Amortization $90.00K $90.00K $90.00K
YoY Change 0.0% 0.0% 0.0%
% of Gross Profit
Operating Expenses $2.650M $1.306M $1.168M
YoY Change 49.72% 11.8% -20.58%
Operating Profit -$2.468M -$2.093M
YoY Change 17.94% -7.94%
Interest Expense $60.00K $3.116K $617.00
YoY Change -97.81% 405.02% -100.24%
% of Operating Profit
Other Income/Expense, Net $181.0K $234.3K
YoY Change -22.73% -90.98%
Pretax Income -$2.590M -$2.290M -$1.860M
YoY Change -372.63% 23.12% -681.25%
Income Tax
% Of Pretax Income
Net Earnings -$2.590M -$2.287M -$1.858M
YoY Change -372.63% 23.07% -673.49%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$3.453M -$4.241M -$23.25M
COMMON SHARES
Basic Shares Outstanding 5.368M shares 7.564M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q4 2016 Q3 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.44M $5.650M $2.470M
YoY Change 196.37% 128.74% -78.67%
Cash & Equivalents $11.50M $5.650M $2.473M
Short-Term Investments
Other Short-Term Assets $750.0K $500.0K $510.0K
YoY Change 127.27% -1.96% 45.71%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $12.19M $6.140M $2.973M
YoY Change 191.63% 106.54% -75.06%
LONG-TERM ASSETS
Property, Plant & Equipment $1.440M $1.460M $1.801M
YoY Change -16.69% -18.95% -14.68%
Goodwill $1.675M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.00K $20.00K $11.87K
YoY Change -15.77% 68.46% 0.0%
Total Long-Term Assets $3.130M $3.160M $3.489M
YoY Change -8.38% -9.42% -8.16%
TOTAL ASSETS
Total Short-Term Assets $12.19M $6.140M $2.973M
Total Long-Term Assets $3.130M $3.160M $3.489M
Total Assets $15.32M $9.300M $6.462M
YoY Change 101.68% 43.93% -58.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.420M $1.090M $580.0K
YoY Change 108.82% 87.93% -49.12%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $90.00K $150.0K $240.0K
YoY Change -64.0% -37.5% 118.18%
Total Short-Term Liabilities $1.630M $1.430M $5.476M
YoY Change -71.4% -73.88% 165.15%
LONG-TERM LIABILITIES
Long-Term Debt $10.00K $10.00K $160.0K
YoY Change -88.89% -93.75% -55.56%
Other Long-Term Liabilities $150.0K $150.0K $150.0K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Liabilities $151.8K $160.0K $305.8K
YoY Change -36.74% -47.67% -39.46%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.630M $1.430M $5.476M
Total Long-Term Liabilities $151.8K $160.0K $305.8K
Total Liabilities $1.785M $1.580M $5.781M
YoY Change -70.0% -72.67% 124.94%
SHAREHOLDERS EQUITY
Retained Earnings -$70.79M -$65.56M
YoY Change 9.57% 15.84%
Common Stock $104.00 $76.00
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $13.54M $7.720M $680.2K
YoY Change
Total Liabilities & Shareholders Equity $15.32M $9.300M $6.462M
YoY Change 101.64% 43.93% -58.9%

Cashflow Statement

Concept 2016 Q4 2016 Q3 2015 Q3
OPERATING ACTIVITIES
Net Income -$2.590M -$2.287M -$1.858M
YoY Change -372.63% 23.07% -673.49%
Depreciation, Depletion And Amortization $90.00K $90.00K $90.00K
YoY Change 0.0% 0.0% 0.0%
Cash From Operating Activities -$2.350M -$2.210M -$2.170M
YoY Change 57.72% 1.84% 3.33%
INVESTING ACTIVITIES
Capital Expenditures -$60.00K -$10.00K -$10.00K
YoY Change 200.0% 0.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$60.00K -$10.00K -$10.00K
YoY Change 200.0% 0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.210M -60.00K -190.0K
YoY Change 183.1% -68.42% -101.58%
NET CHANGE
Cash From Operating Activities -2.350M -2.210M -2.170M
Cash From Investing Activities -60.00K -10.00K -10.00K
Cash From Financing Activities 8.210M -60.00K -190.0K
Net Change In Cash 5.800M -2.280M -2.370M
YoY Change 317.27% -3.8% -123.84%
FREE CASH FLOW
Cash From Operating Activities -$2.350M -$2.210M -$2.170M
Capital Expenditures -$60.00K -$10.00K -$10.00K
Free Cash Flow -$2.290M -$2.200M -$2.160M
YoY Change 55.78% 1.85% 2.86%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q3 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
177912 USD
CY2016Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3116 USD
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-2286860 USD
CY2016Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
181028 USD
CY2016Q3 us-gaap Costs And Expenses
CostsAndExpenses
2467888 USD
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2467888 USD
us-gaap Costs And Expenses
CostsAndExpenses
6971054 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
525111 USD
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
834888 USD
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1305610 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2595979 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-6971054 USD
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
526024 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-913 USD
us-gaap Net Income Loss
NetIncomeLoss
-6445943 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3310248 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3491259 USD
us-gaap Costs And Expenses
CostsAndExpenses
6801507 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-6801507 USD
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
3201004 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3206307 USD
CY2016Q3 us-gaap Restructuring Costs
RestructuringCosts
0 USD
CY2015Q3 us-gaap Restructuring Costs
RestructuringCosts
89848 USD
us-gaap Restructuring Costs
RestructuringCosts
0 USD
us-gaap Restructuring Costs
RestructuringCosts
180348 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
411516 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
208387 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-5933450 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5258 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-5258 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
1811 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
7726885 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1788177 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9422627 USD
us-gaap Interest Paid
InterestPaid
3702 USD
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
6824 USD
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.46
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.02
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-8.53
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5368235 shares
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
756370 shares
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-858 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-354067 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
95014 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6718646 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
39787 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-39787 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
2310 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-191667 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-6950100 USD
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2472527 USD
us-gaap Interest Paid
InterestPaid
43597 USD
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-1475 USD
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
652516 USD
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0 USD
clrb Proceeds From Deferred Issuance Costs
ProceedsFromDeferredIssuanceCosts
38569 USD
clrb Proceeds From Deferred Issuance Costs
ProceedsFromDeferredIssuanceCosts
-129656 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
150633 USD
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
1392000 USD
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
0 USD
clrb Payment Towards Clinical Trial Agreements
PaymentTowardsClinicalTrialAgreements
199000 USD
CY2015Q3 us-gaap Share Based Compensation
ShareBasedCompensation
165016 USD
CY2016Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1237000 USD
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Two
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearTwo
527000 USD
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Three
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearThree
374000 USD
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Four
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearFour
162000 USD
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Current Year
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInCurrentYear
174000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
46.68
CY2016Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
3.19
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
428093 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.97
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.59
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
52738 shares
CY2016Q3 clrb Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Unvested Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedOutstandingNumber
435404 shares
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
52738 shares
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
64.84
CY2016Q3 clrb Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedExercisableWeightedAverageExercisePrice
3.92
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
64.84
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
29182 USD
CY2016Q3 clrb Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue
321122 USD
CY2016Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
29182 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y7M6D
clrb Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingWeightedAverageRemainingContractualTerm
P9Y7M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y7M6D
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
488142 shares
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.51
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
475300 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
49549 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.22
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
70933 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
78.63
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
8542 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
143.75
CY2016Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2015Q4 clrb Registered Direct Offering Shares Of Common Stock
RegisteredDirectOfferingSharesOfCommonStock
101727 shares
clrb Gross Proceeds From Offering
GrossProceedsFromOffering
3300000 USD
clrb Net Proceeds From Offering
NetProceedsFromOffering
2868000 USD
clrb Percentage Of Liquidated Damages Per Month
PercentageOfLiquidatedDamagesPerMonth
0.05 pure
CY2016Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
4629842 shares
CY2016Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
533065 shares
CY2015Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
747592 shares
CY2016Q3 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
55000 USD
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2016-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Registrant Name
EntityRegistrantName
Cellectar Biosciences, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001279704
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Trading Symbol
TradingSymbol
CLRB
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5368235 shares
CY2016Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2016Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000 shares
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000 shares
CY2016Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2016Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5368235 shares
CY2016Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5368235 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
858140 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
858140 shares
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
182283 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
59701 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7371121 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2015Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
55000 USD
CY2016Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-10 reverse split
CY2016Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
At a special meeting held on February 8, 2016, the Companys stockholders approved an amendment to the Companys certificate of incorporation to effect a reverse split of the Companys common stock at a ratio between 1:5 to 1:10 in order to ensure that adequate authorized but unissued shares would be available for anticipated future financings, and to satisfy requirements for the continued listing of the Companys common stock on the NASDAQ Capital Market. In addition, the proposal approved by the stockholders provided that if the reverse split was effected, the number of shares of common stock that the Company is authorized to issue remained unchanged at 40,000,000. The Companys stockholders further authorized the board of directors to determine the ratio at which the reverse split would be effected by filing an appropriate amendment to the Companys certificate of incorporation. The board of directors authorized the ratio of the reverse split and corresponding reduction in authorized shares on February 24, 2016, and effective at the close of business on March 4, 2016, the Companys certificate of incorporation was amended to effect a 1-for-10 reverse split of the Companys common stock (the 2016 Reverse Split). All share and per share numbers included in these consolidated financial statements give effect to the 2016 Reverse Split

Files In Submission

Name View Source Status
0001144204-16-133257-index-headers.html Edgar Link pending
0001144204-16-133257-index.html Edgar Link pending
0001144204-16-133257.txt Edgar Link pending
0001144204-16-133257-xbrl.zip Edgar Link pending
clrb-20160930.xml Edgar Link completed
clrb-20160930.xsd Edgar Link pending
clrb-20160930_cal.xml Edgar Link unprocessable
clrb-20160930_def.xml Edgar Link unprocessable
clrb-20160930_lab.xml Edgar Link unprocessable
clrb-20160930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v452389_10q.htm Edgar Link pending
v452389_ex31-1.htm Edgar Link pending
v452389_ex31-2.htm Edgar Link pending
v452389_ex32-1.htm Edgar Link pending